BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Polyangiitis Market – Forecast to 2030,’ thoroughly examines the Polyangiitis industry to provide essential data & information for the targeted readers.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip’ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules, announced today its plans to focus on treating CNS disorders.

Creative Medical Technology Holdings, Inc. today announced the peer reviewed publication of positive, two-year follow-up data for the Company’s StemSpine® study, showing significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of the Honestly HD website, which aims to provide information, inspiration and resources to help people understand what to expect with Huntington’s Disease chorea – one of the most visible and treatable symptoms of HD – and, how to talk to their doctor about preserving independence.

The latest market analysis report published by Reports and Data, titled ‘Global Purpura Treatment Market – Forecast to 2030,’ thoroughly examines the Purpura Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Polycythemia Market – Forecast to 2030,’ thoroughly examines the Polycythemia industry to provide essential data & information for the targeted readers.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® (brincidofovir), the first oral antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox, from Chimerix.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 14,700 shares of the Company’s common stock at an exercise price per share of $25.21, which was the closing price on September 23, 2022, and restricted stock units to acquire a total of 7,350 shares of the Company’s common stock.

Renovacor, Inc. (NYSE: RCOR) today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference.

Agios Pharmaceuticals, Inc. announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Financial Officer, Cecilia Jones.